Extended Analysis of HIV Infection in Cisgender Men and Transgender Women Who Have Sex with Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083

Mark A. Marzinke(Family Health International 360), Susan H. Eshleman(Johns Hopkins University), Susan L. Ford(Research Triangle Park Foundation), Jessica M. Fogel(Johns Hopkins University), Amber Moser(Johns Hopkins University), Adeola Adeyeye(National Institutes of Health), Myron S. Cohen(University of North Carolina at Chapel Hill), Beatriz Grinsztejn(Fundação Oswaldo Cruz), Kenneth H. Mayer(Miriam Hospital), Suwat Chariyalertsak(Chiang Mai University), Deborah Persaud(Johns Hopkins University), Estelle Piwowar‐Manning(Johns Hopkins University), Marty St. Clair(Coe College), Roberto C. Arduino, John W. Mellors(Textron Systems (United Kingdom)), Raphael J. Landovitz(APLA Health), Marybeth McCauley(Family Health International 360), James F. Rooney(Gilead Sciences (United States)), Elias K. Halvas(University of Pittsburgh), Craig W. Hendrix(Unknown), Peter L. Anderson(University of Colorado Denver), Ryan Kofron(APLA Health), Lane R. Bushman(University of Colorado Anschutz Medical Campus), Brett Hanscom(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Alex R. Rinehart, Zhe Wang(Peking University), Pradip Bhandari(Johns Hopkins University), Lei Weng(Fred Hutch Cancer Center), Ryann Gollings(Johns Hopkins University)

Antimicrobial Agents and Chemotherapy

March 30, 2023

Cited by 30

|New England Journal of Medicine|2011|7k

|New England Journal of Medicine|2012|3.3k

|New England Journal of Medicine|2021|2.6k

|New England Journal of Medicine|1997|1.9k

|New England Journal of Medicine|2016|1.7k

Related Papers